News

Rivaroxaban again shows superior efficacy to enoxaparin

A successful team: Dr. Alexander Straub, Dr. Elisabeth Perzborn and Dr. Susanne Röhrig (from left) of Bayer HealthCare developed rivaroxaban.

Zoom image

A successful team: Dr. Alexander Straub, Dr. Elisabeth Perzborn and Dr. Susanne Röhrig (from left) of Bayer HealthCare developed rivaroxaban.

Berlin – The active substance rivaroxaban has once again demonstrated superior efficacy to enoxaparin in a Phase III study. The anticoagulant, which is undergoing clinical development, was investigated in the RECORD4 study in patients who had undergone total knee replacement surgery. It was found that rivaroxaban (future brand name: Xarelto®) more effectively prevents venous thromboembolism (VTE) than the U.S.-approved treatment regimen with enoxaparin. The once-daily oral administration of rivaroxaban was compared to a twice-daily injection of enoxaparin.

The results of the RECORD 1, 2 and 3 studies, which were recently published in the New England Journal of Medicine and The Lancet, were correspondingly positive. Those studies included patients who had had total hip replacement surgery and others who had undergone hip and knee replacement surgery. In all studies, rivaroxaban was shown to be highly effective in preventing thrombosis.

The European Committee for Medicinal Products for Human Use (CHMP) recently recommended approval of rivaroxaban for the prevention of venous thromboembolism after planned hip or knee replacement surgery. The European Commission is expected to issue its final decision within the next few months, allowing rivaroxaban to be marketed in all E.U. member states.